Pharmacogenomics and bioinformatics: PharmGKB.

The NIH initiated the PharmGKB in April 2000. The primary mission was to create a repository of primary data, tools to track associations between genes and drugs, and to catalog the location and frequency of genetic variations known to impact drug response. Over the past 10 years, new technologies have shifted research from candidate gene pharmacogenetics to phenotype-based pharmacogenomics with a consequent explosion of data. PharmGKB has refocused on curating knowledge rather than housing primary genotype and phenotype data, and now, captures more complex relationships between genes, variants, drugs, diseases and pathways. Going forward, the challenges are to provide the tools and knowledge to plan and interpret genome-wide pharmacogenomics studies, predict gene-drug relationships based on shared mechanisms and support data-sharing consortia investigating clinical applications of pharmacogenomics.

[1]  Joshua M. Stuart,et al.  Integrating genotype and phenotype information: an overview of the PharmGKB project , 2001, The Pharmacogenomics Journal.

[2]  Russ B Altman,et al.  Indexing pharmacogenetic knowledge on the World Wide Web. , 2003, Pharmacogenetics.

[3]  Russ B Altman,et al.  Genetics. Genomic research and human subject privacy. , 2004, Science.

[4]  Zhen Lin,et al.  Genomic Research and Human Subject Privacy , 2004, Science.

[5]  Joanne S. Luciano,et al.  PAX of mind for pathway researchers. , 2005, Drug discovery today.

[6]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[7]  R B Altman,et al.  The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response , 2007, Clinical pharmacology and therapeutics.

[8]  David Haussler,et al.  The UCSC genome browser database: update 2007 , 2006, Nucleic Acids Res..

[9]  T. Tabone.  Mutations, structural variations, and genome‐wide resequencing: where to from here in our understanding of disease and evolution? , 2008, Human mutation.

[10]  Russ B. Altman,et al.  PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single‐drug pharmacogenetics , 2008, Human mutation.

[11]  R B Altman,et al.  An XML‐based interchange format for genotype–phenotype data , 2008, Human mutation.

[12]  Muin J Khoury,et al.  The need for genetic variant naming standards in published abstracts of human genetic association studies , 2009, BMC Research Notes.

[13]  R. Altman,et al.  PharmGKB: understanding the effects of individual genetic variants. , 2008, Drug metabolism reviews.

[14]  R. Altman,et al.  Very important pharmacogene summary: sulfotransferase 1A1. , 2009, Pharmacogenetics and genomics.

[15]  R. Altman,et al.  Cytochrome P450 2D6. , 2009, Pharmacogenetics and genomics.

[16]  Clive E. Bowman,et al.  Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions , 2009, The Pharmacogenomics Journal.

[17]  D. Goldstein.  Common genetic variation and human traits. , 2009, The New England journal of medicine.

[18]  Russ B. Altman,et al.  Pharmspresso: a text mining tool for extraction of pharmacogenomic concepts and relationships from full text , 2009, BMC Bioinformatics.

[19]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[20]  P. Sullivan,et al.  Pharmacogenomic genome-wide association studies: lessons learned thus far. , 2009, Pharmacogenomics.

[21]  Derek J Van Booven,et al.  Cytochrome P450 2C9-CYP2C9. , 2010, Pharmacogenetics and genomics.

[22]  R. Altman,et al.  Very important pharmacogene summary: thiopurine S-methyltransferase. , 2010, Pharmacogenetics and genomics.

[23]  R. Altman,et al.  KCNH2 pharmacogenomics summary. , 2010, Pharmacogenetics and genomics.

[24]  Li Gong,et al.  VKORC1 pharmacogenomics summary. , 2010, Pharmacogenetics and genomics.

[25]  R. Altman,et al.  DNATwist: A Web‐Based Tool for Teaching Middle and High School Students About Pharmacogenomics , 2010, Clinical pharmacology and therapeutics.

[26]  R. Altman,et al.  Very important pharmacogene summary ADRB2 , 2010, Pharmacogenetics and genomics.

[27]  R. Altman,et al.  PharmGKB summary: very important pharmacogene information for angiotensin-converting enzyme , 2010, Pharmacogenetics and genomics.

[28]  David Haussler,et al.  The UCSC Genome Browser database: update 2010 , 2009, Nucleic Acids Res..

[29]  S. Yamaori,et al.  Cannabidiol, a Major Phytocannabinoid, as a Potent Atypical Inhibitor for Cytochrome P450 2D6 , 2011 .

[30]  R. Altman,et al.  Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). , 2011, Pharmacogenetics and genomics.

[31]  Prostaglandins and Other Lipid Mediators sophageal cancer proliferation is mediated by cytochrome P 450 2 C 9 ( CYP 2 C 9 ) , 2011 .

[32]  Marisa Wong Medina,et al.  PharmGKB: very important pharmacogene--HMGCR. , 2011, Pharmacogenetics and genomics.